BridgeBio Pharma, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $502.1M | $221.9M | $9.3M | $77.6M | $69.7M |
| Operating income | -$523.4M | -$593.0M | -$607.4M | -$512.2M | -$576.6M |
| Cost of revenue | $21.0M | $3.9M | $2.4M | $3.4M | $2.7M |
| Cash from operations | -$445.9M | -$520.7M | -$527.7M | -$419.5M | -$497.9M |
| Capital expenditure | $1.1M | $933,000 | $1.3M | $4.8M | $13.2M |
| Free cash flow | -$447.0M | -$521.7M | -$529.0M | -$424.3M | -$511.2M |
| Share repurchases | $48.3M | $0 | $0 | $0 | $200.0M |
| Impairments | $0 | $271,000 | $0 | $12.7M | $0 |
| Total assets | $936.0M | $919.3M | $546.4M | $623.0M | $1.0B |
| Total liabilities | $3.0B | $2.4B | $1.9B | $1.9B | $1.9B |
Shares outstanding 195.9M · Free float 76.3%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.